AN2 Therapeutics (ANTX) Net Income towards Common Stockholders (2021 - 2026)
AN2 Therapeutics (ANTX) reported Net Income towards Common Stockholders of -$10.0 million for Q1 2026, up 5.83% year-over-year from -$9.5 million in Q1 2025, and down 15.13% quarter-over-quarter from -$8.7 million in Q4 2025.
AN2 Therapeutics (ANTX) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$10.0 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$10.0 million, up 5.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.6 million (up 23.81% YoY), and the FY2025 annual result was -$35.2 million, up 31.46% from the prior year.
- Net Income towards Common Stockholders retreated to -$10.0 million in Q1 2026 per ANTX's latest filing, from -$8.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$6.5 million in Q2 2025 and troughed at -$16.9 million in Q4 2023.
- A 5-year average of -$12.0 million and a median of -$11.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 237.31% in 2022, then soared 55.49% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.8 million in 2022, then tumbled by 42.7% to -$16.9 million in 2023, then soared by 55.49% to -$7.5 million in 2024, then fell by 15.79% to -$8.7 million in 2025, then dropped by 15.13% to -$10.0 million in 2026.
- Business Quant data shows ANTX's Net Income towards Common Stockholders at -$10.0 million in Q1 2026, -$8.7 million in Q4 2025, and -$9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -10.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.03 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Sep 30, 2025 | -9.35 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Mar 31, 2025 | -10.65 Mn |
| Dec 31, 2024 | -7.52 Mn |
| Sep 30, 2024 | -12.75 Mn |
| Jun 30, 2024 | -14.44 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -16.90 Mn |
| Sep 30, 2023 | -16.71 Mn |
| Jun 30, 2023 | -15.80 Mn |
| Mar 31, 2023 | -15.32 Mn |
| Dec 31, 2022 | -11.84 Mn |
| Sep 30, 2022 | -11.34 Mn |
| Jun 30, 2022 | -10.12 Mn |
| Mar 31, 2022 | -9.48 Mn |
| Dec 31, 2021 | -9.47 Mn |
| Sep 30, 2021 | -8.87 Mn |
| Jun 30, 2021 | -6.91 Mn |